Your browser doesn't support javascript.
CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.
Haun, Brien K; Lai, Chih-Yun; Williams, Caitlin A; Wong, Teri Ann S; Lieberman, Michael M; Pessaint, Laurent; Andersen, Hanne; Lehrer, Axel T.
  • Haun BK; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Lai CY; Cell and Molecular Biology Graduate Program, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Williams CA; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Wong TAS; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Lieberman MM; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Pessaint L; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Andersen H; BIOQUAL, Inc., Rockville, MD, United States.
  • Lehrer AT; BIOQUAL, Inc., Rockville, MD, United States.
Front Immunol ; 11: 599587, 2020.
Article in English | MEDLINE | ID: covidwho-1116675
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adjuvants, Immunologic / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.599587

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adjuvants, Immunologic / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.599587